Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; a plan to reduce clinician burnout at the computer; and an FDA advisory panel has recommended approval for semaglutide, a once-weekly GLP-1 receptor agonist.
Read more about the stories in this episode:
Deal Reached to Keep Health Insurance Subsidies
The Academy of Managed Care Pharmacy (AMCP) Nexus 2017
Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel
AMA Seeks to Make Health Data Work Better for Doctors, Patients
ACO & Emerging Healthcare Delivery Coalition® Fall 2017
FDA Panel Gives Nod to Once-Weekly Semaglutide for Type 2 Diabetes
Evidence-Based Oncology | October 2017
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More